Using a Clostridium difficile glutamate dehydrogenase (GDH) immunoassay and a sensitive C. difficile toxin A/B immunoassay, human stool specimens from patients with diarrhoea (n51085) were classified as either GDH positive/toxin negative, or GDH positive/toxin positive. Overall, 528/725 (73%) of the GDH-positive/toxin-negative specimens contained viable C. difficile, and 433/528 (82%) of these C. difficile isolates were PCR positive for the toxin gene pathogenicity locus. Overall, 867/1078 (80%) of the GDH-positive specimens contained viable C. difficile, and 433/725 (60%) of the GDH-positive/toxin-negative specimens contained a toxigenic C. difficile strain. The diversity of toxigenic C. difficile ribotypes isolated from toxin-negative specimens (n5433) and toxin-positive specimens (n5339) was significantly different (P,0.0001). Specifically, the presence of ribotype 078 strains was very strongly associated (P,0.0001) with detection of toxin in clinical specimens using a sensitive toxin immunoassay. Specimens positive for ribotype 078 were almost twice as likely to be toxin positive as opposed to toxin negative (risk ratio51.90, 95% confidence interval 1.64-2.19). In contrast, other circulating ribotypes were seen with similar frequency in specimens with and without detectable toxin. This supports the view that ribotype 078 strains may be more virulent than other common ribotypes in terms of toxin production.
INTRODUCTIONHospital laboratories commonly diagnose Clostridium difficile infection by detection of toxin A and/or B in stool specimens using enzyme immunoassay (EIA) tests, although these tests have unacceptably low sensitivity when they are used alone. Depending on the toxin EIA used, positive predictive values are as low as 15-56% when testing patient populations with low prevalence (Eastwood et al., 2009). UK guidance now recommends dual testing using two different tests to improve diagnostic accuracy for C. difficile infection (Robotham & Wilcox, 2012). Immunoassays to detect the glutamate dehydrogenase (GDH) antigen are more sensitive than toxin EIA tests for detection of C. difficile, and many clinical laboratories have adopted GDH tests for screening, with secondary or parallel testing using a toxin EIA test. Dual testing using two assays with different sensitivities generates a significant number of discrepant GDH-positive/toxin-negative results, in addition to definitive GDH-positive/toxin-positive results that confirm a diagnosis of C. difficile infection. Because GDH tests are not specific for toxigenic strains of C. difficile, interpreting these discrepant results can be difficult.The emergence of virulent C. difficile strains is of concern because a highly virulent epidemic C. difficile clone (ribotype 027/NAP1/toxinotype III) has spread globally during the last decade (He et al., 2013). Ribotype 027 strains have been reported to produce significantly more toxin than other strains in vitro. One study reported that 027 strains produced peak titres of toxin A and B that were 16 and 23 times hi...